Life sciences
re-imagined

Vine explores novel approaches to conscious health & wellness

Philosophy

Philanthropy is in our DNA. 50% of our profits are donated back to the mental health community.

Vine is rethinking venture capital for a novel approach to health and wellness.

Representative Companies

Example high-integrity teams that we work with.
Bright minds logoPsygen logoBexson Biomedical logoTripp logo

Team

Ryan Zurrer photo
Ryan Zurrer
Read bio
Ozan Polat
Read bio
Robbie Bent photo
Robbie Bent
Read bio

Ryan Zurrer has been a venture investor and entrepreneur for 16 years. He is an avid biohacker and was an early contributing member to the Quantified Self Movement in the early 2000s. Ryan was a seed investor in some of the best performing venture investments of the 2010s including MakerDAO, Ethereum, Polychain Capital, and a host of other companies.

Ryan launched Polychain’s private investment activities and is considered the creator of the SAFT. Ryan led Polychain Capital’s investment team and was instrumental in delivering Polychain's 2017 returns (in excess of 28X net of fees to LPs).

Ryan has built a reputation for being a hands-on, value-add venture investor with a uniquely global purview. Previously he was CEO of a large Brazilian renewables firm and is responsible for more than 1GW of wind and solar power development globally along with a range of innovations in contracting, financial instruments, and execution of utility-scale renewable energy projects.

Ryan is an honours graduate of the Richard Ivey School of Business where he received the Certificate of Entrepreneurship as well as the Continuing Athletics Scholarship as a member of the Men’s varsity Rugby team.

Ozan Polat is an investor with Vine.

Driven by his intrinsic curiosity, he previously co-founded Dezentrum, a think tank that researches & prototypes positive future scenarios for the digitized society of tomorrow and Trust Square, a technology hub in the heart of Zurich.

The same curiosity and hunger for innovative approaches to our society’s future drove him to Vine Ventures and its novel approach to health & wellness.

Robbie Bent works with Vine and is co-founder and CEO at Othership, a global community to improve mental health in an accessible way. Othership combines beautiful social spaces that deliver peak experiences and a mobile app that teaches breathwork. Prior to Othership, Robbie was Ecosystem Growth lead at the Ethereum Foundation. He graduated from the Richard Ivey School of Business.

We are hiring!

Please email us at connect@vine.vc for more information.

Blog

Investments

Thesis

Vine Ventures: The Next Chapter

Investments

Othership

Why we led Othership’s $8M Series A

News

Top Venture Capital Investors in the Psychedelics Industry

Business Insider's Yeji Jesse Lee breaks down the top 11 venture capital investors in terms of dollars deployed into the growing psychedelics industry.

Psychedelics at a Crossroads: We Need Constructive Not Extractive Capital

In her recent thoughtful and well-researched article for Vice, Shayla Love asked, “Is it possible to create an ethical psychedelics company?” A lot of focus in the psychedelics space over the last few months has centered around the unethical behavior of select companies—David Bronner himself has weighed in. Our take is that it’s not only possible to create an ethical psychedelics company, but that such companies already exist. We want to move the discourse towards creating an ethical psychedelics industry as a whole.

How to Invest in Psychedelic Companies

Our founding partner Ryan Zurrer joins the team at Business Trip to outline the Vine philosophy and our perspective on where the future of psychedelics should head.

Third Wave Podcast

Investing in Our Psychedelic Future

After a successful career in entrepreneurship and cryptocurrency, Ryan Zurrer turned his attention to the burgeoning psychedelic space. As he continued to learn more via research, attending conferences, and speaking with others, he became concerned about what he considers the “dystopian future” of psychedelic therapies – sterile doctors’ offices, $8000 treatments, synthetic drugs, no community or connection.